Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials

PURPOSE: Two phase I, open-label trials in healthy subjects assessed whether co-administration with CYP3A4/CYP2C19 inhibitors, itraconazole/fluconazole (study A), or CYP3A4 inducer, rifampicin (study B), affects the exposure, safety/tolerability and pharmacokinetics of selumetinib and its metabolite...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Clin Pharmacol
Hlavní autoři: Dymond, Angela W., So, Karen, Martin, Paul, Huang, Yifan, Severin, Paul, Mathews, David, Lisbon, Eleanor, Mariani, Gabriella
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2016
Témata:
Pharmacokinetics and Disposition
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226997/
https://ncbi.nlm.nih.gov/pubmed/27889832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00228-016-2153-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky